BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
November 27 2019 - 8:30AM
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a
rapidly growing commercial-stage specialty pharmaceutical company
dedicated to patients living with chronic conditions, today
announced that Herm Cukier, Chief Executive Officer, will
participate in an analyst-led fireside chat at the upcoming Piper
Jaffray 31st Annual Healthcare Conference taking place December 3 -
5, 2019 in New York, NY.
Event: |
Piper Jaffray 31st Annual Healthcare Conference |
Date: |
Wednesday, December 4, 2019 |
Time: |
12:00pm – 12:25pm Eastern Time |
Location: |
Lotte New York Palace, New York, NY |
The management team will also host one-on-one
investor meetings at the conference. For investors attending the
Piper Jaffray conference, please contact BDSI Investor Relations to
schedule a meeting with management at tpatel@bdsi.com.
About BioDelivery Sciences
International, Inc.
BioDelivery Sciences International, Inc.
(NASDAQ: BDSI) is a commercial-stage specialty pharmaceutical
company dedicated to patients living with chronic conditions. BDSI
has built a portfolio of products that includes utilizing its novel
and proprietary BioErodible MucoAdhesive (BEMA®) technology to
develop and commercialize, either on its own or in partnership with
third parties, new applications of proven therapies aimed at
addressing important unmet medical needs. BDSI's marketed products
and those in development address serious and debilitating
conditions such as chronic pain, breakthrough cancer pain, opioid
dependence, and opioid-induced constipation.
Cautionary Note on Forward-Looking
Statements
This press release and any statements of
employees, representatives, and partners of BDSI related thereto
contain, or may contain, among other things, certain
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such forward-looking
statements involve significant risks and uncertainties. Such
statements may include, without limitation, statements with respect
to the BDSI’s plans, objectives, projections, expectations and
intentions and other statements identified by words such as
“projects,” “may,” “will,” “could,” “would,” “should,” “believes,”
“expects,” “anticipates,” “estimates,” “intends,” “plans,”
“potential” or similar expressions. These statements are based upon
the current beliefs and expectations of the BDSI’s management and
are subject to significant risks and uncertainties, including those
detailed in the BDSI’s filings with the Securities and Exchange
Commission. Actual results may differ materially from those set
forth or implied in the forward-looking statements. These
forward-looking statements involve certain risks and uncertainties
that are subject to change based on various factors (many of which
are beyond the BDSI’s control) including those set forth in our
2018 annual report on Form 10-K filed with the US Securities and
Exchange Commission and subsequent filings. BDSI undertakes no
obligation to publicly update any forward-looking statements,
whether as a result of new information, future presentations or
otherwise, except as required by applicable law.
© 2019 BioDelivery Sciences International,
Inc. All rights reserved.
Contact:
Tirth T. PatelDirector of Investor
Relationstpatel@bdsi.com(919) 582-0294
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioDelivery Sciences (NASDAQ:BDSI)
Historical Stock Chart
From Sep 2023 to Sep 2024